I don't have data to speak specifically to that demarcation.
I can certainly say that in the pharmaceutical world and in life sciences, we have been struggling to attract global investment to Canada over the last couple of years, and that continues, but that is related to the uncertainty and now, frankly, the devastating implications of the Patented Medicine Prices Review Board changes that have been made, the regulatory changes.